|
NEJM - New drug regimen cures 90% of patients with hepatitis C and cirrhosis. |
 |
 |
|
Eurekalert: Interferon previously was the only agent to show effectiveness against hepatitis C, but patients often relapsed and the therapy caused multiple side effects. The new regimen is interferon-free and consists of several agents — ABT-450/ritonavir, ombitasvir, dasabuvir and ribavirin. Twelve weeks after the last dose, no hepatitis C virus was detected in the bloodstream of 91.8 percent of patients who took the pills for 12 weeks. Among patients treated for 24 weeks, 95.9 percent were virus-free 12 weeks after the end of therapy.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
